leadf
logo-loader
viewOpen Orphan PLC

Open Orphan confirms it is in advanced negotiation with UK government and other partners for a Coronavirus challenge study

"While negotiations continue, it is expected that in the event that a contract is agreed revenue will be in excess of £7mln, being the approximate anticipated revenue for a Coronavirus challenge study as indicated by Open Orphan on May 22, 2020"

Open Orphan PLC -
However, it added, there can be no certainty that these discussions will lead to a new contract until final negotiations are concluded

Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials has noted its recent share price movement and press speculation regarding UK government-funded Coronavirus human challenge studies.

In a brief statement, the company confirmed that it is in advanced negotiation with the government and other partners for a Coronavirus challenge study in the UK.

READ: Open Orphan says Venn Life Sciences subsidiary secures important new contract to support major European pharma company

The group said: "While negotiations continue, it is expected that in the event that a contract is agreed revenue will be in excess of £7mln, being the approximate anticipated revenue for a Coronavirus challenge study as indicated by Open Orphan on May 22, 2020."

However, it added, there can be no certainty that these discussions will lead to a new contract until final negotiations are concluded.

The company said it will update the market in due course as appropriate.

In morning trade on Thursday, Open Orphan shares were 6.4% lower at 17.55p.

Quick facts: Open Orphan PLC

Price: 26.25 GBX

AIM:ORPH
Market: AIM
Market Cap: £174.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan presents at the Proactive One2One virtual conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 day, 1 hour ago

2 min read